Literature DB >> 25093994

Predicting the probability of experiencing clinically significant drug-drug interactions involving boceprevir-containing hepatitis C therapy among patients coinfected with hepatitis C and HIV.

Nimish Patel1, Michael Veve, Mona Nasiri, Steven Bliss, Louise-Anne McNutt, Victoria Lazariu, Christopher Miller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25093994      PMCID： PMC4183897          DOI： 10.1089/apc.2014.0149

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN： 1087-2914            Impact factor:   5.078


× No keyword cloud information.
  7 in total

1.  Estimating the relative risk in cohort studies and clinical trials of common outcomes.

Authors:  Louise-Anne McNutt; Chuntao Wu; Xiaonan Xue; Jean Paul Hafner
Journal:  Am J Epidemiol       Date:  2003-05-15       Impact factor: 4.897

Review 2.  Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes.

Authors:  Yaron Rotman; T Jake Liang
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

3.  Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients.

Authors:  Alice Tseng; Leah Szadkowski; Sharon Walmsley; Irving Salit; Janet Raboud
Journal:  Ann Pharmacother       Date:  2013-11       Impact factor: 3.154

4.  Adherence to screening guidelines for hepatitis C among HIV-positive patients.

Authors:  Sylvie Jonckheere; Anne Vincent; Leila Belkhir; Dunja Wilmes; Bernard Vandercam; Jean Cyr Yombi
Journal:  AIDS Patient Care STDS       Date:  2013-05-19       Impact factor: 5.078

5.  Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States.

Authors:  Omana V Nainan; Miriam J Alter; Deanna Kruszon-Moran; Feng-Xiang Gao; Guoliang Xia; Geraldine McQuillan; Harold S Margolis
Journal:  Gastroenterology       Date:  2006-08       Impact factor: 22.682

Review 6.  A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt.

Authors:  William Sievert; Ibrahim Altraif; Homie A Razavi; Ayman Abdo; Ezzat Ali Ahmed; Ahmed Alomair; Deepak Amarapurkar; Chien-Hung Chen; Xiaoguang Dou; Hisham El Khayat; Mohamed Elshazly; Gamal Esmat; Richard Guan; Kwang-Hyub Han; Kazuhiko Koike; Angela Largen; Geoff McCaughan; Sherif Mogawer; Ali Monis; Arif Nawaz; Teerha Piratvisuth; Faisal M Sanai; Ala I Sharara; Scott Sibbel; Ajit Sood; Dong Jin Suh; Carolyn Wallace; Kendra Young; Francesco Negro
Journal:  Liver Int       Date:  2011-07       Impact factor: 5.828

7.  Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting.

Authors:  Mattias Mandorfer; Berit A Payer; Alexander Niederecker; Gerold Lang; Maximilian C Aichelburg; Robert Strassl; Christoph Boesecke; Armin Rieger; Michael Trauner; Markus Peck-Radosavljevic; Thomas Reiberger
Journal:  AIDS Patient Care STDS       Date:  2014-05       Impact factor: 5.078
  7 in total
  1 in total

1.  A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients.

Authors:  Nimish Patel; Mona Nasiri; Arden Koroglu; Steven Bliss; Melissa Davis; Louise-Anne McNutt; Christopher Miller
Journal:  Infect Dis Ther       Date:  2015-01-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.